Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134147) titled 'Efficacy and safety of ipilimumab in combination with bevacizumab as first-line treatment in advanced cutaneous and acral melanoma: a prospective, single-arm clinical study' on Oct. 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Anyang Tumour Hospital
Condition:
Locally advanced adenocarcinoma of the gastroesophageal junction
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-08
Target Sample Size: Experimental group:34;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=298063
Published by HT Di...